worldwide offices | stay connected | contact | help | sitemap

 
 

 

 

 

Corporate citizenship

Corporate citizenship

Patients 

From laboratory to market, patient needs come first. Our unique healthcare portfolio, our patient-centric approach to R&D and our innovative access programs all benefit patients worldwide.

Business conduct 

Ethical considerations inform all dimensions of our business: research and development, manufacturing and distribution, marketing and sales.

People and communities 

Our associates and communities are key to our success. That's why we ensure living wages for all Novartis associates, and give back through philanthropy and volunteerism.

Environmental care 

We believe environmental stewardship makes good business sense, and we want to be a leader in environmental sustainability.

 

79.5 million patients 
In 2009, our access-to-medicine programs, valued at USD 1.5 billion, reached 79.5 million patients.

5 million patients 
Since 2000, about 5 million people with leprosy have been treated through the use of multi-drug therapy supplied by Novartis.

Key issues

Key issues

As part of our commitment to engage in dialogue with our stakeholders, we state our position on various issues affecting our business.